Investigation for the effect of duloxetine on adolescent depression; Ver. 2
Not Applicable
- Conditions
- Major Depressive Disorder
- Registration Number
- JPRN-UMIN000016192
- Lead Sponsor
- Shiga University of Medical Science
- Brief Summary
discontinued
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
* Remitted or partial remitted patients * Patients with sever inhibition so as not to tolerate CBT, questionnaire and structured interview * Pregnant women * Patients with physical disorder
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Quolity of Life; SF-36v2
- Secondary Outcome Measures
Name Time Method Depression; BDI-II Anxiety; STAI Autistic Tnedency; PARS-TR Attention Deficit and/or Hyperactivity; ADHD-RS
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie duloxetine's efficacy in adolescent major depressive disorder?
How does duloxetine compare to SSRIs like fluoxetine in treating adolescent MDD clinical outcomes?
Which biomarkers correlate with duloxetine response in adolescent depression trials?
What adverse events were reported in duloxetine trials for adolescents and how were they managed?
Are there combination therapies or alternative SNRIs showing promise for adolescent MDD treatment?